2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures

The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. 

What is the pharma forecast for 2024? 

The last year ushered in continued pressures for the pharmaceutical industry regarding supply shortages, drug pricing, manufacturing costs, and digitisation. As we enter 2024, the supply chain and industry are looking to take proactive measures to address ongoing challenges. Significant movements in the industry include: 

• Quality Management Maturity: Predictive maintenance will be a key application in addressing pre-emptive quality control measures. The US FDA’s Center for Drug Evaluation has also launched the Quality Management Maturity Program, aimed at encouraging drug manufacturers to implement tangible and cultural mindset changes concerning quality management. 

• Cross-industry collaboration: Whether it’s for meeting sustainability goals, implementing cutting-edge technologies, or accelerating drug approval timelines, collaboration across the pharmaceutical supply and value chain is no longer just a want – it is a need. 

• Generative AI, machine learning, and digital futures: The rapid rise of generative AI models, machine-learning algorithms, and large language models such as Chat GPT will push pharmaceutical operations beyond current capabilities. Data-oriented manufacturing and Big Data Analytics for regulatory compliance will have a significant impact on all pharma players. 

Continuing challenges for pharma

Reaching sustainability goals across the pharmaceutical supply chain remains a constant conversation within the industry. In 2024, discussions will focus on the management of difficult-to-quantify scope 3 emissions, new regulations for pharma packaging, and how collaboration is a requirement for the dissemination of information and assessments across the industry. 

Excipients are also continuing to see an explosion of interest in 2024. The FDA’s Novel Excipient Pilot Program will start to see the results of their efforts to accelerate approval for excipients. Advancements in personalised medicines, multifunctional ingredients, and advanced therapeutics are also pushing drug manufacturers to look beyond existing excipients that are limiting the kinds of therapeutics available.  

Patent expirations up to 2030 will have a significant impact on drug pricing, manufacturing costs, and ultimately whether patients will receive the treatments they need. Focus from the industry on R&D while outsourcing manufacturing activities can have a substantial effect on managing rising costs of drug manufacturing and in turn, the price of drugs. Though the Inflation Reduction Act might penalise drug manufacturers for increasing drug prices, the increase in outsourcing behaviour might cause a shift for companies to expand into the outsourcing manufacturing businesses. 

2024 Pharma Trends Outlook: download now! 

Keen to know what 2024 will bring for the pharmaceutical industry? Read from our expert contributors and thought-leaders on their predictions for the 12 biggest trends facing the pharmaceutical industry in the next year.

Download our free Trend Report below.